Loading clinical trials...
Loading clinical trials...
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepa...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bausch Health Americas, Inc.
NCT06483737 · Overt Hepatic Encephalopathy
NCT06953921 · Hepatic Encephalopathy
NCT06052176 · Cirrhosis, Hepatic Encephalopathy
NCT04073290 · Hepatic Encephalopathy, Cirrhosis, Liver, and more
NCT04014413 · Crohn Disease, Ulcerative Colitis, and more
Bausch Site 591
Homewood, Alabama
Bausch Site 445
Chandler, Arizona
Bausch Site 453
Sun City, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions